{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:34:24Z","timestamp":1788406464093,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019450","name":"Verastem Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2026.104635","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:21:59Z","timestamp":1773127319000},"page":"104635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Sarah","family":"Hayward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Blaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-247X","authenticated-orcid":false,"given":"Erin Hickey","family":"Zacholski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-4195","authenticated-orcid":false,"given":"Jennifer","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2026.104635_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104635_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104635_bib3","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104635_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104635_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102497","article-title":"Low grade serous ovarian cancer - a rare disease with increasing therapeutic options","volume":"112","author":"Zwimpfer","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/aogs.14518","article-title":"Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: a nationwide study","volume":"102","author":"De Decker","year":"2023","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104635_bib7","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104635_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104635_bib9","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.3390\/cancers16193268","article-title":"Novel targeted agents in advanced and recurrent low-grade serous ovarian cancer: a silver lining in the therapy of a chemoresistant disease?","volume":"16","author":"Onoprienko","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104635_bib10","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"10324","key":"10.1016\/j.ijgc.2026.104635_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2026.104635_bib12","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","article-title":"Low-grade serous carcinoma of the ovary or peritoneum","volume":"27","author":"Gershenson","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104635_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104635_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.970918","article-title":"Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers","volume":"12","author":"Di Lorenzo","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104635_bib16","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/ijgc-2023-004745","article-title":"Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery","volume":"33","author":"Nasioudis","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104635_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104635_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102736","article-title":"Final overall survival results from the GOG281\/LOGS study evaluating trametinib versus physician\u2019s choice standard-of-care therapy for recurrent low-grade serous ovarian cancer (LGSOC)","volume":"35","author":"Gourley","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"32","key":"10.1016\/j.ijgc.2026.104635_bib21","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104635_bib22","series-title":"Prescribing information","year":"2025"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104635_bib23","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104635_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104635_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104635_bib27","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijgc.2026.104635_bib26","series-title":"AACR Annual Meeting, New Orleans, LA","article-title":"The RAF\/MEK clamp VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK","author":"Coma","year":"2022"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/PPO.0000000000000187","article-title":"Therapeutic approaches to RAS mutation","volume":"22","author":"Scott","year":"2016","journal-title":"Cancer J"},{"issue":"36","key":"10.1016\/j.ijgc.2026.104635_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104635_bib30","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF-MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104635_bib31","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijgc.2026.104635_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104635_bib33","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","article-title":"Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial","volume":"31","author":"Banerjee","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104635_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","article-title":"A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors","volume":"77","author":"Shimizu","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104635_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/cells12040617","article-title":"MAPK pathways in ocular pathophysiology: potential therapeutic drugs and challenges","volume":"12","author":"Moustardas","year":"2023","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104635_bib37","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104635_bib38","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104635_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104635_bib42","first-page":"29","article-title":"BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management","volume":"3","author":"Livingstone","year":"2014","journal-title":"Chin Clin Oncol."},{"issue":"2","key":"10.1016\/j.ijgc.2026.104635_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ijgc.2026.104763","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:11:12Z","timestamp":1781525472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X26001660"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104635","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104635"}}